1.945USD-0.77%Mkt Cap: 82.96M USDP/E: —Last update: 2026-06-01
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap82.96M USD
Enterprise Value67.31M USD
Revenue (TTM)—
Gross Profit-10.07M USD
Net Income (TTM)-20.16M USD
Revenue/Share—
Last Price1.945 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.25
PEG—
EV/EBITDA-3.42
EV/Revenue—
P/S—
P/B5.91
EPS (TTM)-0.58
EPS (Forward)-0.60
52W Range
1.41018% of range4.340
52W High4.340 USD
52W Low1.410 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-108.60%
ROA-88.35%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.47M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-13.41%
Net Debt-15.87M USD
Net Debt/EBITDA0.81
Balance Sheet
Debt/Equity0.04
Current Ratio4.69
Quick Ratio4.32
Book Value/Sh0.3300 USD
Cash/Share0.3880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)7.200 USD
Target Range5.000 USD – 8.000 USD
# Analysts5
Ownership
Shares Out.42.65M
Float41.65M
Insiders2.29%
Institutions19.25%
Short Interest
Short Ratio6.2d
Short % Float7.58%
Short % Out.7.41%
Shares Short3.16M
Short (prev mo.)3.33M
Technical
SMA 501.875 (+3.7%)
SMA 2002.198 (-11.5%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)578.38K
Avg Vol (10d)768.13K
Technical Indicators
RSI (14)56.1
MACD-0.0158
MACD Signal-0.0498
MACD Hist.+0.0340
BB Upper2.024 USD
BB Middle1.811 USD
BB Lower1.598 USD
BB Width23.48%
ATR (14)0.1338 USD
Vol Ratio (20d)1.20x